Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Amber L. Johns

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1948-6683; OpenAlex author ID A5037309883, A5129346895. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
120
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: 4 papers · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 6 papers · 2022: 5 papers · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 39

  1. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  2. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  3. Mucinous cystic neoplasms and simple mucinous cysts are two distinct precursors of pancreatic cancer: clinicopathological, genomic, and transcriptomic characte… Co-author DOI 10.1002/path.6437↗
  4. MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. Co-author DOI 10.1016/j.neo.2025.101138↗
  5. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  6. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  7. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  8. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(22)00448-x↗
  9. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Co-author DOI 10.1038/s41586-022-04735-9↗
  10. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  11. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  12. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  13. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  14. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  15. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  16. Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. Co-author DOI 10.1186/s13053-021-00190-1↗
  17. Correction to: Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants Co-author DOI 10.1186/s13053-021-00195-w↗
  18. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  19. MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41388-019-1091-0↗
  20. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  21. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Co-author DOI 10.1038/s41467-019-10968-6↗
  22. Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program. Co-author DOI 10.1186/s13053-019-0129-1↗
  23. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  24. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  25. Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Co-author DOI 10.1126/scitranslmed.aai8504↗
  26. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Co-author DOI 10.18632/oncotarget.13985↗
  27. Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Co-author DOI 10.1016/j.neo.2016.10.011↗
  28. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  29. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  30. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Co-author DOI 10.1158/1078-0432.ccr-15-0426↗
  31. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Co-author DOI 10.18632/oncotarget.2946↗
  32. Clinical and pathologic features of familial pancreatic cancer. First author DOI 10.1002/cncr.28863↗
  33. Genome-wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT-ROBO, ITGA2 and MET signaling. Co-author DOI 10.1002/ijc.28765↗
  34. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  35. Returning individual research results for genome sequences of pancreatic cancer. Co-author DOI 10.1186/gm558↗
  36. Understanding pancreatic cancer genomes. Co-author DOI 10.1007/s00534-013-0610-6↗
  37. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Co-author DOI 10.1186/gm482↗
  38. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  39. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Co-author DOI 10.1093/annonc/mdr561↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anthony James Gill · 18 shared papers, 2012–2026 · strength 1.60
  2. Marina Pajic · 16 shared papers, 2012–2026 · strength 1.12
  3. Andrew Victor Biankin · 17 shared papers, 2012–2023 · strength 1.02
  4. David Goldstein · 9 shared papers, 2013–2026 · strength 0.98
  5. Joshua A. McCarroll · 8 shared papers, 2015–2026 · strength 0.96
  6. Phoebe A. Phillips · 8 shared papers, 2015–2026 · strength 0.96
  7. George Sharbeen · 8 shared papers, 2015–2026 · strength 0.96
  8. Mert Erkan · 6 shared papers, 2015–2026 · strength 0.83
  9. Koroush Shahsavar Haghighi · 5 shared papers, 2021–2026 · strength 0.79
  10. John Kokkinos · 5 shared papers, 2021–2026 · strength 0.79
  11. David Kuang-Fu Chang · 13 shared papers, 2012–2025 · strength 0.77
  12. Jennifer P. Morton · 6 shared papers, 2018–2026 · strength 0.72
  13. Jaswinder Singh Samra · 11 shared papers, 2012–2025 · strength 0.68
  14. Val Gebski · 4 shared papers, 2021–2026 · strength 0.59
  15. Rita Teresa Lawlor · 5 shared papers, 2014–2025 · strength 0.59
  16. Aldo Scarpa Scarpa · 5 shared papers, 2014–2025 · strength 0.59
  17. Australian Pancreatic Cancer Genome Initiative · 4 shared papers, 2014–2026 · strength 0.56
  18. Paul Timpson · 5 shared papers, 2018–2026 · strength 0.51
  19. Angela S. Y. Chou · 8 shared papers, 2013–2021 · strength 0.47
  20. Claudio Luchini · 3 shared papers, 2022–2025 · strength 0.43
  21. Kendelle Joan Murphy · 4 shared papers, 2018–2026 · strength 0.42
  22. Tanya M. Dwarte · 3 shared papers, 2019–2021 · strength 0.33
  23. Alina Stoita · 3 shared papers, 2019–2021 · strength 0.33
  24. Sean Michael Grimmond · 8 shared papers, 2013–2021 · strength 0.32
  25. Antonio Pea · 2 shared papers, 2023–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.